Clearmind Medicine CMND 深 沪
等待开盘 04-02 09:30:00 美东时间
1.08
+0.040
+3.85%
华盛通- 最 高1.08
- 今 开1.06
- 成交量 10.70万股
- 最 低 1.00
- 昨 收 1.04
- 总市值 258.64万
- 52周最高 52.40
- 市盈率 静 --
- 换手率 4.47%
- 52周最低 0.5949
- 委 比 -99.18%
- 总股本 239.48万
- 历史最高 7320.00
- 量 比 0.97
- 振 幅 7.69%
- 历史最低 0.5949
- 每 手 1
- 风险率 17.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Files Patent Application In India Covering Next-Gen Psychedelic-Based Compounds For Treatment Of Mental Health Disorders And Addiction
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived
03-27 19:33
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company, has filed a patent application in India for next-generation psychedelic-based compounds targeting mental health disorders and addiction. This submission, part of the company’s expanding global IP portfolio, builds on its collaboration with Yissum Research. The compounds aim to offer safer, more effective treatments compared to traditional psychedelics. The company currently...
03-27 11:32
Clearmind Medicine To Continue Treatment Of Patients In Third Group Of Its Current FDA-Approved Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived
03-19 21:42
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. announced positive progress in its Phase I/IIa clinical trial of CMND-100 for treating Alcohol Use Disorder (AUD). The third cohort at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center is proceeding successfully with no serious adverse events reported. CMND-100, a non-hallucinogenic MEAI-based oral drug, shows promise as a breakthrough therapy for AUD. The Company’s CEO expressed satisfaction ...
03-19 12:45
Clearmind Medicine Announces Continuation Of Participant Enrollment For Third Cohort Of Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For AUD Treatment
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived
03-11 21:11
Clearmind Medicine's Interim Review For FDA-Approved Phase I/IIa Clinical Study For CMND-100 Completed By Data And Safety Monitoring Board
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation, neuroplastogen-derived
03-04 20:36
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Clearmind Medicine Inc. has announced positive safety results from the second cohort of its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen, in treating Alcohol Use Disorder (AUD). The independent Data and Safety Monitoring Board (DSMB) has recommended continuing the trial following the encouraging additional top-line data, which demonstrated a favorable safety profile and good tolerability. This paves the way for the...
03-04 12:30
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
Clearmind Medicine's proprietary compound MEAI (5-methoxy-2-aminoindane) has been included in U.S. federal legislation for the first time. The bipartisan bill, H.R. 7091, aims to expand access to innovative therapies for veterans, including MEAI, psilocybin, MDMA, and others, to address conditions like alcohol use disorder and PTSD. Clearmind CEO Dr. Adi Zuloff-Shani applauds the legislation, highlighting MEAI's potential to improve veterans' hea...
02-03 13:00
Clearmind Medicine Completes Treatment For All Patients In Second Cohort Of Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For AUD Treatment
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major
01-14 21:57
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Clearmind Medicine Inc. announced the successful completion of treatment for the second cohort in its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder. The six-patient cohort, recruited from leading medical centers, completed the trial following positive results from the first cohort, which showed favorable safety and efficacy signals. The company expects to release top-line results from the second cohort in the coming months.
01-14 13:55
